{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:55:41Z","timestamp":1789750541342,"version":"4.0.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.ejca.2023.112945","type":"journal-article","created":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T15:56:20Z","timestamp":1687190180000},"page":"112945","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials"],"prefix":"10.1016","volume":"190","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8999-2899","authenticated-orcid":false,"given":"Alessandra","family":"Raimondi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8044-4207","authenticated-orcid":false,"given":"Federico","family":"Nichetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1041-0137","authenticated-orcid":false,"given":"Arndt","family":"Stahler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harpreet S.","family":"Wasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Aranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Randon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4352-6788","authenticated-orcid":false,"given":"Annika","family":"Kurreck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela M.","family":"Meade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"D\u00edaz-Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Niger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3297-5801","authenticated-orcid":false,"given":"Sebastian","family":"Stintzing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Palermo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Trarbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5596-469X","authenticated-orcid":false,"given":"Michele","family":"Prisciandaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greta","family":"Sommerh\u00e4user","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5306-3596","authenticated-orcid":false,"given":"Federica","family":"Morano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8530-8420","authenticated-orcid":false,"given":"Filippo","family":"Pietrantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik P.","family":"Modest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejca.2023.112945_bib1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis,\u00a0treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2023.112945_bib2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2005.03.0106","article-title":"OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer\u2014a GERCOR study","volume":"24","author":"Tournigand","year":"2006","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2023.112945_bib3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1634\/theoncologist.2011-0249","article-title":"First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study","volume":"17","author":"Diaz-Rubio","year":"2012","journal-title":"Oncologist"},{"issue":"34","key":"10.1016\/j.ejca.2023.112945_bib4","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1200\/JCO.2009.23.4344","article-title":"Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? the GERCOR OPTIMOX2 study","volume":"27","author":"Chibaudel","year":"2009","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2023.112945_bib5","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S1470-2045(11)70102-4","article-title":"Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial","volume":"12","author":"Adams","year":"2011","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.ejca.2023.112945_bib6","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/S1470-2045(15)00042-X","article-title":"Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial","volume":"16","author":"Hegewisch-Becker","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2023.112945_bib7","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/annonc\/mdv011","article-title":"Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41\/06)","volume":"26","author":"Koeberle","year":"2015","journal-title":"Ann Oncol"},{"issue":"9980","key":"10.1016\/j.ejca.2023.112945_bib8","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(14)62004-3","article-title":"Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the dutch colorectal cancer group","volume":"385","author":"Simkens","year":"2015","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ejca.2023.112945_bib9","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1470-2045(14)70106-8","article-title":"Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial","volume":"15","author":"Wasan","year":"2014","journal-title":"Lancet Oncol"},{"issue":"3_suppl","key":"10.1016\/j.ejca.2023.112945_bib10","article-title":"Maintenance treatment with cetuximab versus observation in RAS wild-type metastatic colorectal cancer: results of the randomized phase II PRODIGE 28-time UNICANCER study","volume":"39","author":"Boige","year":"2021","journal-title":"J\u00a0Clin\u00a0Oncol"},{"key":"10.1016\/j.ejca.2023.112945_bib11","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ejca.2018.06.024","article-title":"First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: phase II randomised MACRO2 TTD study","volume":"101","author":"Aranda","year":"2018","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.ejca.2023.112945_bib12","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/jamaoncol.2019.1467","article-title":"Maintenance therapy with panitumumab alone versus panitumumab plus fluorouracil-leucovorin in patients with RAS wild-type metastatic colorectal cancer: a phase 2 randomized clinical trial","volume":"5","author":"Pietrantonio","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2023.112945_bib13","doi-asserted-by":"crossref","first-page":"158e167","DOI":"10.1016\/j.ejca.2019.07.006","article-title":"SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer","volume":"119","author":"Munemoto","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.112945_bib14","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1200\/JCO.21.01332","article-title":"Panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS wild-type metastatic colorectal cancer: the randomized PANAMA trial (AIO KRK 0212)","volume":"40","author":"Modest","year":"2021","journal-title":"J Clin Oncol"},{"issue":"suppl_7","key":"10.1016\/j.ejca.2023.112945_bib15","first-page":"S808","article-title":"Phase III study with FOLFIRI\/cetuximab versus FOLFIRI\/cetuximab followed by cetuximab (Cet) alone in first-line therapy of RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients: the ERMES study","volume":"33","author":"Pinto","year":"2022","journal-title":"Ann Oncol"},{"issue":"16_suppl","key":"10.1016\/j.ejca.2023.112945_bib16","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1200\/JCO.2022.40.16_suppl.3503","article-title":"Randomized intermittent or continuous panitumumab plus FOLFIRI (FOLFIRI\/PANI) for first-line treatment of patients (pts) with RAS\/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): the IMPROVE study","volume":"40","author":"Avallone","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.112945_bib17","first-page":"599","article-title":"NCCN guidelines updates: management of metastatic colorectal cancer","volume":"17","author":"Messersmith","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ejca.2023.112945_bib18","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejca.2018.12.019","article-title":"Treatment sequencing in metastatic colorectal cancer","volume":"109","author":"Modest","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.112945_bib19","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nrclinonc.2015.129","article-title":"First-line chemotherapy for mCRC-a review and evidence-based algorithm","volume":"12","author":"Cremolini","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2023.112945_bib20","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.4489","article-title":"The role of maintenance strategies in metastatic colorectal cancer: a systematic review and network meta-analysis of randomized clinical trials","volume":"6","author":"Sonbol","year":"2020","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2023.112945_bib21","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1001\/jamaoncol.2018.5070","article-title":"Cost-effectiveness of maintenance capecitabine and bevacizumab for metastatic colorectal cancer","volume":"5","author":"Sherman","year":"2019","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2023.112945_bib22","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S1470-2045(16)30269-8","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial","volume":"17","author":"Stintzing","year":"2016","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2023.112945_bib23","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1016\/S1470-2045(20)30527-1","article-title":"Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials","volume":"21","author":"Andr\u00e9","year":"2020","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2023.112945_bib24","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.annonc.2021.03.206","article-title":"Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines","volume":"32","author":"Grothey","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2023.112945_bib25","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejca.2020.11.017","article-title":"Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer","volume":"144","author":"Manca","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.112945_bib26","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejca.2022.09.011","article-title":"Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: an analysis of the PanaMa trial (AIO KRK 0212)","volume":"178","author":"Sommerh\u00e4user","year":"2023","journal-title":"Eur J Cancer"},{"issue":"33","key":"10.1016\/j.ejca.2023.112945_bib27","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1200\/JCO.19.01254","article-title":"Negative hyperselection of patients with RAS and BRAF wild-type metastatic colorectal cancer who received panitumumab-based maintenance therapy","volume":"37","author":"Morano","year":"2019","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2023.112945_bib28","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/nm.3870","article-title":"Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients","volume":"21","author":"Siravegna","year":"2015","journal-title":"Nat Med"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923002976?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923002976?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:42:06Z","timestamp":1760733726000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923002976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":28,"alternative-id":["S0959804923002976"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.112945","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.112945","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"112945"}}